|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE03
|
|
gptkbp:bioavailability
|
around 60%
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:chemical_formula
|
C22 H26 FN3 O2 S
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
oncology
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to sunitinib
|
|
gptkbp:discontinued
|
no
|
|
gptkbp:dosage_form
|
gptkb:capsule
50 mg once daily
|
|
gptkbp:effective_date
|
gptkb:2006
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:financials
|
DB01280
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sutent
|
|
gptkbp:ingredients
|
gptkb:sunitinib
|
|
gptkbp:interacts_with
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:lifespan
|
40-60 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_education
|
important for understanding treatment
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:provides_guidance_on
|
available for use
|
|
gptkbp:research_areas
|
cancer therapy
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
required during treatment
|
|
gptkbp:second_line_treatment
|
yes
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
diarrhea
cardiovascular events
high blood pressure
skin rash
thrombocytopenia
neutropenia
hemorrhage
thyroid dysfunction
mouth sores
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:VEGFR
gptkb:PDGFR
KIT
CSF1 R
|
|
gptkbp:treatment
|
yes
possible
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
treatment of kidney cancer
treatment of gastrointestinal stromal tumors
|
|
gptkbp:bfsParent
|
gptkb:sunitinib
|
|
gptkbp:bfsLayer
|
7
|